RNAi therapeutics: Principles, prospects and challenges

被引:672
作者
Aagaard, Lars [1 ]
Rossi, John J. [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA
关键词
siRNA; shRNA; RNAi; RNA interference; antisense; miRNA; RISC;
D O I
10.1016/j.addr.2007.03.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other antisense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 116 条
  • [1] RNA silencing and genome regulation
    Almeida, R
    Allshire, RC
    [J]. TRENDS IN CELL BIOLOGY, 2005, 15 (05) : 251 - 258
  • [2] Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients
    Amado, RG
    Mitsuyasu, RT
    Rosenblatt, JD
    Ngok, FK
    Bakker, A
    Cole, S
    Chorn, N
    Lin, LS
    Bristol, G
    Boyd, MP
    Macpherson, JL
    Fanning, GC
    Todd, AV
    Ely, JA
    Zack, JA
    Symonds, GP
    [J]. HUMAN GENE THERAPY, 2004, 15 (03) : 251 - 262
  • [3] Algorithm for selection of functional siRNA sequences
    Amarzguioui, M
    Prydz, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 316 (04) : 1050 - 1058
  • [4] Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation
    Bagga, S
    Bracht, J
    Hunter, S
    Massirer, K
    Holtz, J
    Eachus, R
    Pasquinelli, AE
    [J]. CELL, 2005, 122 (04) : 553 - 563
  • [5] Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages
    Banerjea, A
    Li, MJ
    Bauer, G
    Remling, L
    Lee, NS
    Rossi, J
    Akkina, R
    [J]. MOLECULAR THERAPY, 2003, 8 (01) : 62 - 71
  • [6] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [7] Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
    Bartlett, DW
    Davis, ME
    [J]. NUCLEIC ACIDS RESEARCH, 2006, 34 (01) : 322 - 333
  • [8] Progress towards in vivo use of siRNAs
    Behlke, MA
    [J]. MOLECULAR THERAPY, 2006, 13 (04) : 644 - 670
  • [9] Dicer is essential for mouse development
    Bernstein, E
    Kim, SY
    Carmell, MA
    Murchison, EP
    Alcorn, H
    Li, MZ
    Mills, AA
    Elledge, SJ
    Anderson, KV
    Hannon, GJ
    [J]. NATURE GENETICS, 2003, 35 (03) : 215 - 217
  • [10] Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo
    Bertrand, JR
    Pottier, M
    Vekris, A
    Opolon, P
    Maksimenko, A
    Malvy, C
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (04) : 1000 - 1004